Juno Therapeutics, Inc. (NASDAQ:JUNO)‘s stock had its “in-line” rating reissued by equities researchers at Leerink Swann in a note issued to investors on Thursday. They currently have a $56.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $34.00. Leerink Swann’s price target would suggest a potential upside of 24.69% from the stock’s current price.
A number of other equities research analysts have also weighed in on the stock. Morgan Stanley restated an “equal weight” rating and issued a $43.00 price objective (up from $27.00) on shares of Juno Therapeutics in a report on Friday, October 6th. Cowen and Company reiterated a “buy” rating and set a $49.00 price target on shares of Juno Therapeutics in a report on Friday, October 27th. Vetr upgraded shares of Juno Therapeutics from a “strong sell” rating to a “sell” rating and set a $25.50 price target for the company in a report on Monday, August 14th. Zacks Investment Research lowered shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 28th. Finally, Raymond James Financial, Inc. upgraded shares of Juno Therapeutics from a “market perform” rating to an “outperform” rating and set a $45.00 price target for the company in a report on Tuesday, August 29th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company. Juno Therapeutics presently has an average rating of “Hold” and a consensus price target of $43.20.
Juno Therapeutics (NASDAQ:JUNO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The business had revenue of $44.80 million during the quarter, compared to analyst estimates of $18.12 million. During the same period in the previous year, the business posted ($0.57) earnings per share. Juno Therapeutics’s revenue for the quarter was up 115.4% on a year-over-year basis.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2017/11/02/juno-therapeutics-inc-juno-earns-in-line-rating-from-leerink-swann.html.
In related news, Director Richard Klausner sold 12,000 shares of the stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $30.34, for a total value of $364,080.00. Following the completion of the sale, the director now directly owns 788,985 shares of the company’s stock, valued at approximately $23,937,804.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Sunil Agarwal sold 7,285 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $44.76, for a total transaction of $326,076.60. The disclosure for this sale can be found here. Insiders sold a total of 85,004 shares of company stock valued at $3,551,561 over the last three months. 15.26% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in JUNO. The Manufacturers Life Insurance Company grew its holdings in Juno Therapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 228 shares in the last quarter. Pacad Investment Ltd. purchased a new stake in Juno Therapeutics during the 2nd quarter valued at approximately $105,000. QS Investors LLC purchased a new stake in Juno Therapeutics during the 2nd quarter valued at approximately $135,000. Macquarie Group Ltd. purchased a new stake in Juno Therapeutics during the 2nd quarter valued at approximately $248,000. Finally, Leisure Capital Management purchased a new stake in Juno Therapeutics during the 2nd quarter valued at approximately $255,000. 67.18% of the stock is owned by institutional investors and hedge funds.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.